Radiation plus abemaciclib for breast cancer that spread to the brain
Original title: SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so it is still checking safety.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests radiation and the drug abemaciclib for a type of breast cancer that has spread to the brain.
Who this trial is for. This trial is for people with HR+/HER2- metastatic breast cancer that has spread to the brain. Everyone in it gets abemaciclib, hormone therapy, and a focused type of radiation called stereotactic radiosurgery: Radiation aimed at a small target, in one visit or a few. There is no cutting, despite the name. See the glossary.
Where it stands. This trial has not reported results. It is looking at how safe this mix of treatments is and how well it works. The answers are not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a study, not care your own doctor can give you. Someone with this type of breast cancer in the brain could ask their care team about it.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, September 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.